| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalvista Pharmaceuticals, Inc. (KALV) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. KALV is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 462.6K | $12.49M | - | |
| Other | 223.5K | $6.03M | - | |
| Other | 142.5K | $3.85M | - | |
| Other | 100.0K | $2.70M | - | |
| Other | 51.4K | $1.39M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2024 | Yea Christopher53 | Chief Development Officer | Sale+OE | 7,192 | $9.26 | $66,572.75 | -7.4% | +5.2% | +53.4% | |
| Nov 18, 2024 | Audhya Paul K. | Chief Medical Officer | Sale+OE | 8,077 | $9.26 | $74,765.56 | -7.9% | +5.2% | +53.4% | |
| Sep 9, 2024 | Palleiko Benjamin L46 | Chief Executive Officer | Sale+OE | 7,352 | $12.19 | $89,621.62 | -2.8% | -21.3% | +31.5% | |
| Aug 23, 2024 | Audhya Paul K. | Chief Medical Officer | Sale+OE | 2,135 | $12.40 | $26,474.00 | -2.5% | -26.2% | +6.2% | |
| Aug 23, 2024 | Yea Christopher53 | Chief Development Officer | Sale+OE | 1,916 | $12.40 | $23,758.40 | -2.2% | -26.2% | +6.2% | |
| Aug 19, 2024 | Audhya Paul K. | Chief Medical Officer | Sale+OE | 7,973 | $12.01 | $95,782.04 | -9.0% | -24.0% | +4.7% | |
| Aug 19, 2024 | Palleiko Benjamin L46 | Chief Executive Officer | Sale+OE | 14,215 | $12.01 | $170,769.06 | -5.5% | -24.0% | +4.7% | |
| Aug 19, 2024 | Yea Christopher53 | Chief Development Officer | Sale+OE | 7,102 | $12.01 | $85,318.46 | -7.8% | -24.0% | +4.7% | |
| Jun 7, 2024 | Palleiko Benjamin L46 | Chief Executive Officer | Sale+OE | 7,465 | $11.53 | $86,068.46 | -3.2% | +10.2% | +23.0% | |
| May 20, 2024 | Feener Edward P.72 | Chief Scientific Officer | Sale+OE | 8,088 | $11.76 | $95,151.28 | -10.0% | +3.0% | +3.0% |